Regenica is developing a dynamic pipeline of next-generation medical countermeasures to biochemical terrorism.
Regenica is focused exclusively on high-quality candidates that display powerful clinical effects and favorable safety profiles. Through ultra-efficient preclinical programs, Regenica quickly derisks candidates to optimize the likelihood of success.
Regenica combines the lean and nimble flexibility of a biotech company with the scaled regulatory efficiency of a government defense firm. This allows Regenica to provide quality therapeutics to vulnerable patient populations in record time.
Regenica’s lead compound, REG-001 is a novel small-molecule antidote protecting against a broad class of weaponized nerve agents.
Regenica plans to develop a vector platform allowing for inoculation and protection against tier-1 select biological agents.